Global Hunter Syndrome Treatment Market Size, Growth Analysis Report, Forecast to 2027


Posted September 13, 2021 by alfahadkhan2510

The global hunter syndrome treatment market is estimated to grow at a CAGR of around 5% during the forecast period.
 
The global hunter syndrome treatment market is estimated to grow at a CAGR of around 5% during the forecast period. Hunter syndrome is also known as Mucopolysaccharidosis type II or MSP II. It is a very rare genetic disorder caused by the malfunction of the enzyme. Hunter syndrome happens due to the deficiency of the enzyme. The enzyme breaks down certain complex sugar molecules, when enzyme deficits in the body these sugar molecules grow up in harmful amounts. By breaking down,this kind of sugar molecule helps to build bones, skins, tendons, and other tissues. When these sugar molecules grow up it damages parts of bodies including the brain.

Free Sample Copy @ https://www.omrglobal.com/request-sample/hunter-syndrome-treatment-market

Hunter syndrome is mainly seen in boys. According to the National MPS Society, 1 in 1,00,000 to 1 in 1,70,000 every male are affected by the hunter syndrome. When a mother is a carrier of MSP II, there is a 50% chance that her baby boy will have the hunter syndrome. Although rare hunter syndrome has been diagnosed in girls too. Girls have less chance of having hunter syndrome as they have two X chromosomes if any of the X chromosomes is defective, then the other normal X chromosome can provide a functional gene. Where a male has only one X chromosome, if it is defective then the male suffers hunter syndrome.

Innovative novel therapies in clinical trials and increasing R&D activities by major market players for the development of hunter syndrome treatment are the major two driving factors of the global hunter syndrome treatment market. For instance, in June 2019, Denali Therapeutics Inc. got approval from the FDA for DNL310, it is used to improve overall clinical manifestations of Hunter syndrome, including both peripheral and neurological symptoms, which are not adequately addressed by currently approved therapies. The high cost involved in the treatment of hunter syndrome is restraining the growth of the global hunter syndrome treatment market. For instance, the current treatment cost for hunter syndrome costs an amount of $250,000 to $500,000 per year per patient.

A Full Report of Global Hunter Syndrome Treatment Market is Available at:
https://www.omrglobal.com/industry-reports/hunter-syndrome-treatment-market

The global hunter syndrome treatment market is segmented based on treatment into Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), and others (Gene Therapy, Bone Marrow Transplant, and Tonsillectomy). There is no cure, however,treatments such as enzyme replacement therapies can help make the disease more manageable. Enzyme replacement therapy (ERT) is an FDA approved medical procedure. This drug is given through an intravenous line oncea week. If enzyme replacement therapy is given at the early stage of hunter syndrome, it may delay or prevent some of the symptoms of Hunter syndrome. Although, in enzyme replacement therapy there are some side effects, such as allergic reactions, headache, fever and skin reactions. Some of the enzyme replacement therapy drugs are Elaprase (idursulfase) by Shire Plc, Hunterase (idursulfase) by GC Pharma, and others.

Global Hunter Syndrome Treatment Market – Segmentation
by Treatment
Enzyme Replacement Therapy (ERT)
Hematopoietic Stem Cell Transplant (HSCT)
Others ( Gene Therapy, Bone Marrow Transplant, Tonsillectomy)

Global Hunter Syndrome Treatment Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World
Company Profiles
ArmaGen, Inc.
Bioasis Technologies, Inc.
Clinigen Group PLC
Denali Therapeutics, Inc.
Esteve Pharmaceuticals, S.A.
GC Pharma Corp.
Inventiva S.A.
JCR Pharmaceuticals Co., Ltd.
REGENXBIO, Inc.
Sangamo Therapeutics, Inc.
Shire Plc. (Takeda Pharmaceutical Company)

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hunter-syndrome-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By alfahad khan
Phone +91 780-304 -0404
Country India
Categories Business
Tags global hunter syndrome treatment market
Last Updated September 13, 2021